Regeneron Reports Strong Q3 Earnings; Pipeline Progress in MASH and POTS
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
What happened
Regeneron Pharmaceuticals reported Q3 2026 revenue of $5.12 billion, which was 36.3% higher than the previous year, and achieved an adjusted EPS of $20.07, surpassing analyst estimates by 23.5%. The company also stated it generated encouraging early results in MASH and POTS, and expects a regulatory decision regarding cemdisiran next month. Furthermore, Regeneron expanded its alliance with Sanofi to include four next-generation antibodies.
From financialcontent.com
Why it matters
The strong financial performance and record net sales for products like Dupixent and EYLEA HD indicate robust market demand for Regeneron’s portfolio. The pipeline progress, including the MASH and POTS data and the cemdisiran regulatory review, suggests continued growth potential in specialized therapeutic areas.
From financialcontent.com
Who's involved
- Regeneron PharmaceuticalsAmerican pharmaceutical company reporting Q3 earnings and pipeline updates
- SanofiFrench pharmaceutical company with which Regeneron expanded its antibody alliance
- FDARegulatory agency expected to make a decision on cemdisiran next month
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- SanofiSpeculative
Sanofi might see increased investment in next-generation antibodies following the expansion of its alliance with Regeneron Pharmaceuticals
How it developed
Newest first. Tap a step to see who reported it.BioTech reports encouraging early data in MASH and POTS, and anticipates FDA decision on cemdisiran.1 source
The companies expanded their immunology alliance and are awaiting the FDA's regulatory decision on cemdisiran.1 source
Keep exploring
The entities involved
- FDA
-
BioTech
company in Prague, Czechia
-
mash
fast genome and metagenome distance estimation using MinHash
Nothing else this week.
Related events
- The FDA requested additional clinical data from Unicycive Therapeutics.
- A company submitted study data supporting a PMA submission to the FDA.
- FDA approved a medical device from Abbott and supported a PARADIGM study based on data from the Cleveland Clinic.
- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
- LabCorp is involved in FDA-approved drugs. Intuitive Surgical's systems were FDA-cleared. Masimo develops noninvasive patient monitoring technologies.